Verzenios Den europeiske union - norsk - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - bryst neoplasms - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Emgality Den europeiske union - norsk - EMA (European Medicines Agency)

emgality

eli lilly nederland b.v. - galcanezumab - migrene lidelser - analgesics, galcanezumab - emgality er indisert for profylakse av migrene hos voksne som har minst 4 migrene dager per måned.

Retsevmo Den europeiske union - norsk - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Rayvow Den europeiske union - norsk - EMA (European Medicines Agency)

rayvow

eli lilly nederland b.v. - lasmiditan succinate - migrene lidelser - analgetika - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Abiraterone Qilu 500 mg Norge - norsk - Statens legemiddelverk

abiraterone qilu 500 mg

qilu pharma spain s.l. - abirateronacetat - tablett, filmdrasjert - 500 mg

Ophthajod 50 mg/ ml Norge - norsk - Statens legemiddelverk

ophthajod 50 mg/ ml

vital pharma nordic aps - povidon, jodert - Øyedråper, oppløsning - 50 mg/ ml

Jaypirca Den europeiske union - norsk - EMA (European Medicines Agency)

jaypirca

eli lilly nederland b.v. - pirtobrutinib - lymfom, mantelcelle - protein kinase hemmere - treatment of mantle cell lymphoma (mcl).